Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz serves as the Chief Medical Physicist at Texas Oncology, merging her professional expertise with her personal experience as a cancer survivor. Her insights into patient care have been shaped not only by her extensive career in oncology but also by her journey as a breast cancer survivor over the past five years. This unique blend of perspectives enhances her ability to connect with patients while driving advancements in medical physics and oncology care.

A dual perspective: Provider and patient

The day Dr. Rosencranz received her cancer diagnosis is etched in her memory. As a seasoned professional familiar with the terminology, she anticipated the diagnosis upon hearing her radiologist mention "spiculated margins." "I kinda knew before the official diagnosis that I have cancer," she reflected, marking the start of her journey from a provider to a patient. This dual experience allows her to empathize deeply with her patients, understanding firsthand the mix of fear and uncertainty that comes with such news.

Dr. Rosencranz's medical journey enhanced her appreciation for personalized care. Her professional network, including friendships with her future chemotherapy and radiation oncologists, provided her with support that most patients lack. This intersection of professional and personal support enables her to empathize with patients on a level beyond clinical assessments.

Embracing innovation in oncology

Throughout her 23-year tenure at Texas Oncology, Dr. Rosencranz has witnessed the evolution of technology in cancer care. She praises the organization's dedication to providing top-tier cancer treatment, particularly in rural areas where travel to urban centers can be challenging. "Texas Oncology penetrates through so many demographics... we are staying online with the highest technology out there," she stated.

Dr. Rosencranz is enthusiastic about the role of artificial intelligence in oncology. She identifies applications like auto-contouring and treatment planning as areas where AI is making significant advancements. However, she emphasizes the necessity of human oversight: "You still need that human leadership in anything that you do." Her message to vendors in the tech industry is straightforward: consistent testing and transparency are essential to building trust and understanding as AI becomes more prevalent in clinical settings.

Her advocacy for AI in oncology is founded on the potential she sees for the technology to transform care, facilitating both efficiency and the creation of personalized treatment plans. Dr. Rosencranz envisions a future where human expertise and AI work in tandem to enhance patient outcomes and push the limits of what's possible in cancer treatment.